Fatty Liver Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for fatty liver. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your fatty liver condition.

Questions? See the Clinical Trials FAQs.


Click below to view clinical trials by areas:

Liver Fibrosis

Condition:

Nonalcoholic steatohepatitis and liver fibrosis

Key Inclusion Criteria:

  • 18-75 years old
  • Evidence of NASH
  • Evidence of Stage 2 or Stage 3 liver fibrosis

Summary:

This study focuses on patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Steatohepatitis is a type of liver disease known as fatty liver, where the cells in the liver have abnormal accumulation of fat. Liver fibrosis develops as a consequence of inflammation and buildup of scar tissue in the liver. The purpose of the study is to determine whether an investigational drug called cenicriviroc (CVC) is safe and effective for the treatment of liver fibrosis in patients with NASH. Participants will be randomly assigned to receive either CVC along with information regarding diet and exercise, or a placebo drug along with information regarding diet and exercise.

Nonalcoholic Steatohepatitis (NASH)

Condition:

Nonalcoholic steatohepatitis and liver fibrosis

Key Inclusion Criteria:

  • 18-75 years old
  • Evidence of NASH
  • Evidence of Stage 2 or Stage 3 liver fibrosis

Summary:

This study focuses on patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Steatohepatitis is a type of liver disease known as fatty liver, where the cells in the liver have abnormal accumulation of fat. Liver fibrosis develops as a consequence of inflammation and buildup of scar tissue in the liver. The purpose of the study is to determine whether an investigational drug called cenicriviroc (CVC) is safe and effective for the treatment of liver fibrosis in patients with NASH. Participants will be randomly assigned to receive either CVC along with information regarding diet and exercise, or a placebo drug along with information regarding diet and exercise.

Condition:

Nonalcoholic Steatohepatitis

Key Inclusion Criteria:

  • 18-75 years old
  • Confirmation of steatohepatitis on a diagnostic liver biopsy
  • Fibrosis Stage 1 or greater and below Stage 4 (according to the NASH Clinical Research Network fibrosis staging system)
  • Body mass index ≤45 kg/m²

Summary:

This study focuses on patients diagnosed with nonalcoholic steatohepatitis (NASH) with fibrosis (recently confirmed by a liver biopsy) or those who are at high risk of having this disease and are willing to undergo a liver biopsy to determine whether they have NASH with fibrosis. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug called elafibranor in these patients. Researchers will assess the efficacy of elafibranor compared to placebo (inactive substance) for the treatment of NASH. The study will also evaluate whether elafibranor reduces the number of patients that will develop further complications from NASH, such as liver cirrhosis.

Condition:

Nonalcoholic steatohepatitis

Participant Requirements:

  • 18-75 years old
  • Confirmation of nonalcoholic steatohepatitis (NASH) on a diagnostic liver biopsy
  • Total NAFLD Activity Score of four or more with at least one in each component of the NAS score

Summary:

This study focuses on individuals diagnosed with nonalcoholic steatohepatitis (NASH) who are overweight or obese and who have prediabetes or Type 2 diabetes. NASH is a chronic liver disease that may cause scarring of the liver and liver failure. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug called aramchol on NASH and NASH-related complications compared to placebo (inactive substance).

Condition:

Nonalcoholic steatohepatitis

Participant Requirements:

  • At least 18 years old
  • History of nonalcoholic fatty liver disease with or without cirrhosis or hepatocellular carcinoma diagnosed within the last 6 months

Summary:

Researchers will evaluate the differences between biomarkers measured in participants’ specimens, clinical data, and questionnaire data in order to learn more about why nonalcoholic fatty liver disease progresses in some people.

Condition:

Nonalcoholic steatohepatitis

Participant Requirements:

  • Confirmed diagnosis of nonalcoholic steatohepatitis
  • 18-75 years old
  • Screening MRI-PDFF with ≥8% liver fat fraction

Summary:

The purpose of this study is to determine the safety and effectiveness of an investigational thyroid hormone receptor drug called VK2809 for the treatment of nonalcoholic steatohepatitis (NASH). VK2809 is designed to reduce cholesterol and lower liver fat content.